Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04543565
Other study ID # BOJI201939F
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 2020
Est. completion date December 2024

Study information

Verified date September 2020
Source Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Contact daidi Wang
Phone +86 029 68790358
Email wangdd@xtyw.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at a ratio of 2:1. Treatment duration will be 96w in randomization and followed by 48w in open. The interim analysis will be conducted when all subject completed the first 48-week treatment.


Description:

this is a randomized, double-blind, positive drug parallel control, multicenter, phase 3 study .Eligible HBeAg-positive or HBeAg-negative chronic hepatitis B patients will be stratified by historical antiviral treatment (untreated or treated) at the time of screening, and then randomly assigned to Pradefovir mesylate tablet group or tenofovir disoproxil fumarate tablet group at a ratio of 2:1. The proportion of subject with compensatory stage of cirrhosis is no more than 20 percentage. Patients will receive a total of 144 weeks of antiviral treatments, and after 96 weeks of double-blind treatment, all subjects will switch to open mesylate Pradefovir tablets for additional 48 weeks. The first 48 weeks are the core period and the followed 96 weeks are the extension period. Statistical analysis was conducted on the efficacy and safety of the whole trial. (After the completion of 48-week visit of the last one subject, the interim analysis will be conducted. The analysts will be unblinded, while the remaining participants will still be blind.


Recruitment information / eligibility

Status Recruiting
Enrollment 900
Est. completion date December 2024
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age from 18 to 65 years old, male or female.

- Meets the diagnosis and treatment standards of chronic hepatitis B( HBsAg or HBV DNA positive over 6 months, or diagnosed by liver biopsy.

- For HBeAg positive, HBV DNA equal or over 20000 IU/ml; for HBeAg negative ,HBV DNA equal or over 2000 IU/ml.

- ALT level between 1.2 ULN to 10 UNL.

- Treatment naive or experienced when any nucleos(t)ide analogs or interferons stopped over 6 months.

- Use of effective contraceptive measures if procreative potential exists.

- Written informed consent.

Exclusion Criteria:

- Allergic to study drug,metabolite product or excipient.

- Evidence of hepatic decompensation such as Child-Pugh B or C, with previous gastroesophageal variceal haemorrhage, hepatic encephalopathy, ascites

- Suspected or confirmed hepatocellular carcinoma, or AFP>50µg/L.

- Other liver diseases (such as Chronic alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease).

- Resistant to antiviral drugs (adefovir or tenofovir).

- Concommitant disease of severe heart, blood, respiratory and central nervous system diseases.

- Chronic kidney diseases, or Ccr<60ml/min at screening.

- Abnormal hematological and biochemical parameters at screening: White blood cell count less than 3.0×109/L,or neutrophil count less than 1.5×109/L,or platelet count less than 80×109/L,or total bilirubin more than 2ULN,or the prolong of PT more than 3s.

- Positive-HCV or positive-HIV.

- Severe bone disease (such as osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, rickets) or multiple fractures.

- History of pancreatitis or malignancy within 5 years (excluding cervical epithelial carcinoma, squamous epithelial carcinoma, or basal cell carcinoma of the skin that was clinically cured within 5 years of diagnosis).

- Plan to receive or have already had an organ transplant.

- Subject with disabilities as prescribed by law (blindness, deafness, deafness, deafness, mental disorders, etc.).

- History of alcohol or drug abuse within the last 1 year.

- Pregnant or lactating women.

- Participated in any clinical trial or taken any IMP (investigational medical product) within 3 months prior to the trial.

- Other cases that could not be enrolled in the judgement of the investigators.

Study Design


Intervention

Drug:
Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet
Once daily
Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate
Once daily

Locations

Country Name City State
China The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary HBV viral suppression proportion of patients with hepatitis B virus(HBV) -DNA undetectable(<29IU/ml) After 48-week therapy
Secondary HBV viral suppression proportion of patients with hepatitis B virus(HBV) -DNA undetectable(<29IU/ml) After therapy of 4, 8, 12, 24, 36, 72, 96, 144 weeks
Secondary HBV viral suppression proportion of patients with hepatitis B virus(HBV) -DNA undetectable(<20IU/ml) After therapy of 4, 8, 12, 24, 48, 36, 72, 96, 144 weeks
Secondary The reduction of HBV DNA load the change of HBV DNA load from baseline at week 4, 8, 12, 24, 36, 48, 72, 96, 144
Secondary ALT normalization proportion of patients with ALT normalization After therapy of 4, 8, 12, 24, 48, 36, 72, 96, 144 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A
Recruiting NCT01360892 - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography N/A